{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:43:33Z","timestamp":1792453413868,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"DOI":"10.1007\/s11481-026-10288-9","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:53:54Z","timestamp":1776059634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness of Rituximab in Treatment-Na\u00efve vs. Switch Patients with Multiple Sclerosis: A Real-World Retrospective Study"],"prefix":"10.1007","volume":"21","author":[{"given":"Hosna","family":"Elshony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakan","family":"Almuhanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Al-Ghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha K.","family":"Almatrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ahmed","family":"Ashshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Uthman","family":"Almatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer","family":"Al-Ghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Tawakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Muddassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"14","key":"10288_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520961839","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA et al (2020) Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler 26(14):1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520961839","journal-title":"Mult Scler"},{"issue":"2","key":"10288_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"7","key":"10288_CR3","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","volume":"19","author":"R Li","year":"2018","unstructured":"Li R, Patterson KR, Bar-Or A (2018) Reassessing B cell contributions in multiple sclerosis. Nat Immunol 19(7):696\u2013707. https:\/\/doi.org\/10.1038\/s41590-018-0135-x","journal-title":"Nat Immunol"},{"issue":"3","key":"10288_CR4","doi-asserted-by":"publisher","first-page":"102027","DOI":"10.1016\/j.xcrm.2025.102027","volume":"6","author":"I Jelcic","year":"2025","unstructured":"Jelcic I, Naghavian R, Fanaswala I, Hebecker M, Schaffert H, Lutterotti A et al (2025) T-bet+ CXCR3\u2009+\u2009B cells drive hyperreactive B\u2013T cell interactions in multiple sclerosis. Cell Rep Med 6(3):102027. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102027","journal-title":"Cell Rep Med"},{"issue":"3","key":"10288_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-023-02037-2","volume":"84","author":"AK Carlson","year":"2024","unstructured":"Carlson AK, Amin M, Cohen JA (2024) Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability. Drugs 84(3):285\u2013304. https:\/\/doi.org\/10.1007\/s40265-023-02037-2","journal-title":"Drugs"},{"issue":"6","key":"10288_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1915330","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Confavreux C, Fox EJ, Giovannoni G et al (2020) Ofatumumab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med 383(6):546\u2013557. https:\/\/doi.org\/10.1056\/NEJMoa1915330","journal-title":"N Engl J Med"},{"key":"10288_CR7","doi-asserted-by":"publisher","first-page":"729726","DOI":"10.3389\/fimmu.2021.729726","volume":"12","author":"G Brancati","year":"2021","unstructured":"Brancati G, Pardini M, Mancuso R, Lapucci C, Bruscolini A, Zagami L et al (2021) Rituximab in multiple sclerosis: a review of real-world evidence. Front Immunol 12:729726. https:\/\/doi.org\/10.3389\/fimmu.2021.729726","journal-title":"Front Immunol"},{"key":"10288_CR8","doi-asserted-by":"publisher","first-page":"1245567","DOI":"10.3389\/fneur.2023.1245567","volume":"14","author":"F Gasc\u00f3n-Gim\u00e9nez","year":"2023","unstructured":"Gasc\u00f3n-Gim\u00e9nez F, Alcal\u00e1 C, Rami\u00f3-Torrent\u00e0 L, Alonso-C\u00e1novas A, Ar\u00e9valo MJ, Blanco Y et al (2023) Treatment of multiple sclerosis with rituximab: a Spanish multicenter experience. Front Neurol 14:1245567. https:\/\/doi.org\/10.3389\/fneur.2023.1245567","journal-title":"Front Neurol"},{"key":"10288_CR9","doi-asserted-by":"publisher","first-page":"120459","DOI":"10.1016\/j.jns.2022.120459","volume":"443","author":"K Sharma","year":"2022","unstructured":"Sharma K, Tolaymat S, Yu H, Gopal A, Sattar A, Malik A et al (2022) Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: a review. J Neurol Sci 443:120459. https:\/\/doi.org\/10.1016\/j.jns.2022.120459","journal-title":"J Neurol Sci"},{"issue":"4","key":"10288_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/ane.12968","volume":"138","author":"SG Berntsson","year":"2018","unstructured":"Berntsson SG, Kristoffersson A, Bostr\u00f6m I, Andersen O, Lycke J (2018) Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden \u2013 outlier or predecessor? Acta Neurol Scand 138(4):327\u2013331. https:\/\/doi.org\/10.1111\/ane.12968","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"10288_CR11","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4(10):e296. https:\/\/doi.org\/10.1371\/journal.pmed.0040296","journal-title":"PLoS Med"},{"issue":"11","key":"10288_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452. https:\/\/doi.org\/10.1212\/WNL.33.11.1444","journal-title":"Neurology"},{"key":"10288_CR13","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda (MD): U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2017) Nov 27. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"issue":"8","key":"10288_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/1352458517720043","volume":"24","author":"T Spelman","year":"2018","unstructured":"Spelman T, Frisell T, Piehl F, Hillert J (2018) Comparative effectiveness of rituximab relative to interferon-\u03b2 or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler 24(8):1087\u20131095. https:\/\/doi.org\/10.1177\/1352458517720043","journal-title":"Mult Scler"},{"issue":"8","key":"10288_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson A et al (2022) Rituximab versus dimethyl fumarate in relapsing\u2013remitting multiple sclerosis (RIFUND-MS): a multicentre, randomized, open-label, phase 3 trial. Lancet Neurol 21(8):693\u2013703","journal-title":"Lancet Neurol"},{"issue":"7","key":"10288_CR17","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1111\/ene.15330","volume":"29","author":"A Moreira","year":"2022","unstructured":"Moreira A, Munteis E, Vera A, Tintor\u00e9 M, R\u00edo J, Nos C et al (2022) Delayed B-cell repopulation after rituximab treatment in multiple sclerosis patients with expanded adaptive natural killer cells. Eur J Neurol 29(7):2015\u20132023. https:\/\/doi.org\/10.1111\/ene.15330","journal-title":"Eur J Neurol"},{"key":"10288_CR18","doi-asserted-by":"publisher","unstructured":"Rowles WM, Hsu WY, McPolin K, Kister I, Rimler Z, Kuhle J et al (2022) Transitioning from S1P receptor modulators to B-cell-depleting therapies in multiple sclerosis: clinical, radiographic, and laboratory data. Neurology: Neuroimmunology & Neuroinflammation. ;9(4):e1183. https:\/\/doi.org\/10.1212\/NXI.0000000000001183","DOI":"10.1212\/NXI.0000000000001183"},{"key":"10288_CR19","doi-asserted-by":"publisher","unstructured":"de Souza Wagner PH, de Paiva FA, Mello JS, de Oliveira LM, Damasceno A, Damasceno B (2025) Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis. J Neurol. https:\/\/doi.org\/10.1007\/s00415-025-12845-7","DOI":"10.1007\/s00415-025-12845-7"},{"issue":"2","key":"10288_CR20","doi-asserted-by":"publisher","first-page":"205521732110155","DOI":"10.1177\/20552173211015503","volume":"7","author":"MG Sotiropoulos","year":"2021","unstructured":"Sotiropoulos MG, Lokhande H, Healy BC, Chitnis T, Dreyer A, Paul A et al (2021) Relapse recovery in multiple sclerosis: effect of treatment and contribution to long-term disability. Multiple Scler J \u2013 Experimental Translational Clin 7(2):20552173211015503. https:\/\/doi.org\/10.1177\/20552173211015503","journal-title":"Multiple Scler J \u2013 Experimental Translational Clin"},{"key":"10288_CR21","doi-asserted-by":"publisher","first-page":"1500763","DOI":"10.3389\/fneur.2025.1500763","volume":"15","author":"AA Fernandes","year":"2025","unstructured":"Fernandes AA, Neves AL, Ferro D, Correia M, Marques A, Sousa L et al (2025) Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study. Front Neurol 15:1500763. https:\/\/doi.org\/10.3389\/fneur.2025.1500763","journal-title":"Front Neurol"},{"key":"10288_CR22","doi-asserted-by":"publisher","unstructured":"Langer-Gould AM, Smith JB, Gonzales EG, Piehl F, Li BH (2023) Multiple sclerosis, disease-modifying therapies, and infections. Neurology: Neuroimmunology & Neuroinflammation. ;10(6):e200164. https:\/\/doi.org\/10.1212\/NXI.0000000000200164","DOI":"10.1212\/NXI.0000000000200164"},{"issue":"1","key":"10288_CR23","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1212\/NXI.0000000000001115","volume":"9","author":"M Perriguey","year":"2022","unstructured":"Perriguey M, Maarouf A, Stellmann JP, Heesen C, Trebst C, Schammler S (2022) Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab. Neurology: Neuroimmunol Neuroinflammation 9(1):e1115. https:\/\/doi.org\/10.1212\/NXI.0000000000001115","journal-title":"Neurology: Neuroimmunol Neuroinflammation"},{"issue":"1","key":"10288_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/vaccines9010012","volume":"9","author":"G Jalkh","year":"2020","unstructured":"Jalkh G, Abi Nahed R, Macaron G, Rensel M (2020) Safety of newer disease-modifying therapies in multiple sclerosis. Vaccines 9(1):12. https:\/\/doi.org\/10.3390\/vaccines9010012","journal-title":"Vaccines"},{"key":"10288_CR25","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","volume":"14","author":"J de S\u00e8ze","year":"2023","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, Vermersch P, Zephir H, Moreau T et al (2023) Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol 14:1004795. https:\/\/doi.org\/10.3389\/fimmu.2023.1004795","journal-title":"Front Immunol"},{"issue":"6","key":"10288_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/jnnp-2024-335704","volume":"96","author":"B Yamout","year":"2025","unstructured":"Yamout B, Alroughani R, Mohamed SFA, Al-Tahan S, Bohlega S, Al-Shubaili Y et al (2025) Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study. J Neurol Neurosurg Psychiatry 96(6):567\u2013575. https:\/\/doi.org\/10.1136\/jnnp-2024-335704","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-026-10288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-026-10288-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-026-10288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:53:58Z","timestamp":1776059638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-026-10288-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10288"],"URL":"https:\/\/doi.org\/10.1007\/s11481-026-10288-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7118548\/v1","asserted-by":"object"}]},"ISSN":["1557-1904"],"issn-type":[{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki. Given the retrospective design of the study, informed consent was waived, and all patient data were anonymized to safeguard confidentiality. The study protocol received approval from the Security Forces Hospital Makkah (SFHM) Institutional Review Board (IRB), which is registered with the National BioMedical Ethics Committee under King Abdulaziz City for Science and Technology on 7\/7\/1436 (Registration number: HAP-02-K-052). The IRB approval number is [0749-081024], dated November 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"18"}}